Introduction
Foreword
As we celebrate our centennial, I look back to our beginnings with
amazement and with pride at the similarity of our operations, our concerns, our
challenges, our successes, and the quality of our people. In 1956, during our
50th anniversary, a book of articles, prepared by members of
the Food and Drug Administration and a few close observers, was published. This
book, entitled The Impact of the Food and Drug Administration on Our
Society1, served as the inspiration for this foreword.
Our Commissioner in 1956, George P. Larrick, wrote: “The most
important task of this government bureau is to protect consumers against
harmful, insanitary, and falsely labeled foods, drugs, cosmetics, therapeutic
devices, and the like.” Charles Wesley Dunn, President of The Food Law Institute
put it this way: “The FDA has a tremendous responsibility of protecting every
man, woman and child in this country from death or injury by the adulteration or
misbranding of food and drugs, and it has successfully met this responsibility,
notwithstanding the handicap of inadequate appropriations.”
Today, we continue to protect and advance public health through
assuring compliance with FDA laws and regulations. Mr. Dunn described our law as
“a great public law of profound social and economic importance to our country.”
Associate Commissioner for Laboratories, Robert Roe, predicted that the laws of
1956 would be inadequate for the future as “The future problems of the atomic
age will require that the legislation keep pace as far as possible with
scientific advances and, particularly, that the enforcing agency be provided
with facilities, including trained manpower, to administer effectively such
legislation in the protection of consumers.” Our laws have indeed evolved in our
second fifty years and must continue to evolve to fully support our noble
mission.
To ensure the safety and integrity of the products we regulate,
FDA conducts inspections and surveillance of establishments throughout the
nation, at ports of entry, and in foreign countries. We collect and analyze
samples to determine their safety, effectiveness, quality, purity, and
truthfulness of labeling.
Fifty years ago, the Agency carried out its work with 1033 people,
571 of whom were assigned to field laboratories and inspection offices.
Today, our Agency has grown tenfold and our field force has grown
more than fourfold yet the observation of Chief Inspector Franklin
Clark in 1956 remains a current reality. He described the inspectors
and chemists as public servants of the highest order and “without
their unflagging interest, ingenuity, and accuracy, the American
consumer would soon become the victim of caveat emptor.” To accomplish the mission, the inspectors and chemists,
through research, study, and resourcefulness were able to meet the challenge of
swift technologic advancements in products and manufacturing technology. Mr.
Clark concluded, “These public servants are fully aware of their tremendous
responsibility. Their pride and satisfaction in the essential job they are doing
together is great. The security of the contents of our medicine chests, our
refrigerators, and our pantries is in good hands.” Joseph Maguire,
Assistant Chief Counsel appreciated how court contests begin with the work of
our educated and highly qualified inspectors. “Their training and instructions,”
he reported “are directed to the execution of the minutiae of each assignment
with such a degree of attention to detail that the work product, if subjected to
judicial scrutiny, would not be found wanting.” The sample he described as
“meticulously documented, identified, and sealed.”
Commissioner Larrick described the field staff as the eye and ears
of the Agency and the factory inspection as “the keystone of FDA enforcement.”
He notes that in most instances, our inspections find the facility inspected to
be beyond reproach but on the occasions where the firm’s output is suspect,
shipments are traced, samples are analyzed, and corrective action ensues. “The
basic philosophy of the Food and Drug Administration is to use every proper
procedure to try to prevent violations of the law.” Commissioner Larrick
recognized the importance of educating firms to provide knowledge of what the
law requires and also that our industry had a keen sense of their
responsibility. Our resources, therefore, could be focused on fringe groups that
are either careless or culpable. “When significant and substantial violations of
the law are uncovered, it is the policy of the Food and Drug Administration to
pursue their prosecution with vigor.”
In a letter to a physician in his hometown, the head of our San
Francisco district wrote, “It is fortunate indeed that in the 50 years since the
Wiley law went into effect, the vast majority of those who produce foods, drugs,
devices, and cosmetics have accepted fully their responsibility to the American
consumer, thus permitting our little group to concentrate on the heedless, the
careless, and the greedy.”
Henry Lepper, an attorney with the Department of Health, Education
and Welfare, succinctly described the role of enforcement: “The public largely
assumes that everything it buys is safe, clean and truthfully and informatively
labeled. It is the enforcement official’s responsibility to make and keep it
so.”
A strong, effective, and efficient enforcement of FDA laws and
regulations is essential to our mission of protecting and promoting public
health. Enforcement actions also play an important part in ensuring that the
American people can have confidence in the safety, quality and integrity of the
U.S. food and medical supplies.
Effective enforcement sends an important message to industry that
there is a price to pay for violating FDA laws and regulations by offering
unsafe or ineffective products to the consumer. Whenever the Agency learns of
unsafe or illegal products, it moves swiftly to take whatever appropriate
actions are needed to protect the public and assure full compliance with the
law.
The Agency has a range of actions it can take in these instances
yet the basic tools of 1956 remain in place: seizure, injunction, and
prosecution. For less serious, less threatening breaches, we seek informal means
to achieve compliance. More formal written warnings are issued in other
situations whereby we expect prompt corrections to achieve full compliance with
the law. Violators who do not heed these warnings, however, or whose
actions pose a more serious public health risk may be subject to more formal and
severe measures. The Enforcement Story outlines the Agency's significant
enforcement accomplishments over the past year -- including seizures,
injunctions, prosecutions, disqualification of clinical investigators, civil
money penalty cases, examples of the types of Warning Letters issued, and
recalls. Through case studies and statistics, The Enforcement Story highlights
the crucial work performed by our FDA inspectors, investigators, criminal
investigators, analysts, compliance officers, and others in the field and in our
Centers who work to ensure that products used by consumers are both safe and
effective.
When looking to the future, Commissioner Larrick’s words from 1956
ring true today. He described the Agency as being at a crossroads, faced with
significant technologic developments, population growth, increased volume of
products, discovery of new drug products, and repeated amendments to the law.
With his finger on the pulse of the country, he noted “There appears to be a
growing realization on the part of the consuming public, and particularly in the
affected industries, that a strengthened FDA is desirable not only from the
standpoint of the American public but from the standpoint of the industries as
well.”
As FDA moves into our next 100 years, I pray that we are able to
honor the generations before us by continuing on their path, learning, and
teaching the generation that follows. “If we can see farther than our ancestors,
it is because we are standing on their shoulders.”
It is my pleasure to present The Enforcement Story of 2005.
Respectfully,
David K. Elder
Director, Office of Enforcement
Office of
Regulatory Affairs
_______________________________
1). The Impact of the Food and Drug Administration on Our Society,
Edited by Henry Welch, Ph.D. and Felix Marti-Ibanez, MD. Published by MD
Publications, New York, New York, 1956.
|